Find My Journal

BJ

B Jolain

Independent Researcher

8

Publications

217

Citations

4

H-Index

3

i10-Index

0

2yr Mean Cite

-

Cite/Paper

Data combined from OpenAlex . OA = OpenAlex S2 = Semantic Scholar

Verify on Google Scholar

Publication & Citation Trends

Most Cited Works

Variability of Cost-Effectiveness Estimates for Pharmaceuticals in Western Europe: Lessons for Inferring Generalizability

Marco Barbieri, Michael Drummond, Richard J. Willke, J Chancellor, B Jolain +1 more

Value in Health 2005

129

Early Modelling for Assessing Health and Economic Outcomes of Drug Therapy

Lieven Annemans, Bernard Genesté, B Jolain

Value in Health 2000

60

Is paclitaxel and cisplatin a cost-effective first-line therapy for advanced ovarian carcinoma? OA

Allan Covens, Sylvain Boucher, Kathie Roche, Moira Macdonald, Daniel Pettitt +3 more

Cancer 1996

17

Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer after 5-FU failure

Clemens A. Schmitt, G.H. Blijham, B Jolain, P. Rougier, E Van Cutsem

Anti-Cancer Drugs 1999

7

Letters to the editor

B Jolain, Daniel Pettitt

Clinical Therapeutics 1995

2

Publications

8 total

Variability of Cost-Effectiveness Estimates for Pharmaceuticals in Western Europe: Lessons for Inferring Generalizability

Marco Barbieri, Michael Drummond, Richard J. Willke, J Chancellor, B Jolain et al. - Value in Health, 2005

Cited by 129 OpenAlex

PHP4 ARE THE RESULTS OF ECONOMIC EVALUATIONS GENERALIZABLE? EVIDENCE FROM STUDIES OF PHARMACEUTICALS IN WESTERN EUROPE PDF

Marco Barbieri, MF Drummond, R.J. Willke, J Chancellor, B Jolain et al. - Value in Health, 2003

Cited by 1 OpenAlex

Early Modelling for Assessing Health and Economic Outcomes of Drug Therapy

Lieven Annemans, Bernard Genesté, B Jolain - Value in Health, 2000

Cited by 60 OpenAlex

Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer after 5-FU failure

Clemens A. Schmitt, G.H. Blijham, B Jolain, P. Rougier, E Van Cutsem - Anti-Cancer Drugs, 1999

Cited by 7 OpenAlex

OP4. Cost-effectiveness of Irinotecan (CPT-11) and best estimated chemotherapy regimen in patients with metastatic colorectal cancer after failure of 5fluorouracil (5FU) containing regimen: Results based on a phase III trial

G.H. Blijham, Clemens A. Schmitt, Pierre Aussage, B Henry-Launois, B Jolain et al. - European Journal of Cancer, 1997

Cited by 1 OpenAlex

PP56. A model of patients' preferences for chemotherapy outcomes in advanced colorectal cancer: Do gains in survival justify the toxicity?

Clemens A. Schmitt, B Henry-Launois, B Jolain, MC Cavallo, LG Mantovani - European Journal of Cancer, 1997

Cited by 0 OpenAlex

Is paclitaxel and cisplatin a cost-effective first-line therapy for advanced ovarian carcinoma? PDF

Allan Covens, Sylvain Boucher, Kathie Roche, Moira Macdonald, Daniel Pettitt et al. - Cancer, 1996

Cited by 17 OpenAlex

Letters to the editor

B Jolain, Daniel Pettitt - Clinical Therapeutics, 1995

Cited by 2 OpenAlex

Research Topics

Health Systems, Economic Evaluations, Quality of Life (3) Pharmaceutical Economics and Policy (3) Colorectal Cancer Treatments and Studies (2) Pancreatic and Hepatic Oncology Research (1) Ovarian cancer diagnosis and treatment (1)

Frequent Co-Authors

CL

Clemens A. Schmitt

3 joint publications

MA

Marco Barbieri

2 joint publications

J

J Chancellor

2 joint publications

AD

Adrian Towse

2 joint publications

DA

Daniel Pettitt

2 joint publications

G.

G.H. Blijham

2 joint publications

Affiliations

Utrecht University

NL 1999 - 1999

Institut Gustave Roussy

FR 1999 - 1999

Sanofi (France)

FR 2000 - 2000

Bristol-Myers Squibb (Canada)

CA 1996 - 1996

Anton Proksch Institut

AT 1999 - 1999

External Profiles

OpenAlex Profile Search Semantic Scholar Google Scholar

Share Profile

Back to Researchers